Seeking Investors: First-in-Class Immunotherapeutics for Cancer
ATLANTA, Jan. 27, 2025 /PRNewswire/ -- Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical studies. The drug is mutation-agnostic, and the...
AXA and HK Express Launch New Flight Delay Parametric Protection
More Travel Protection Products for Better Flexibility Expanding into More Markets HONG KONG, Dec. 9, 2024 /PRNewswire/ -- AXA Hong Kong and Macau (AXA) and HK Express Airways (HK Express), with the support of AXA Partners, are pleased to announce...
